Researchers extracted energy-producing structures from a patient’s own muscle cells and injected them into her eyes, opening an experimental new frontier in regenerative medicine — even though the early results stopped short of restoring sight.

Scientists have carried out what is believed to be the first mitochondrial transplant into the human eye, testing an experimental approach that could eventually offer a new way to treat conditions in which damaged cells lose their ability to produce enough energy.

The procedure involved extracting healthy mitochondria — the microscopic structures responsible for producing much of a cell’s usable energy — from a patient’s own leg muscle and injecting them into the vitreous fluid of her eyes.

The experiment did not restore the patient’s vision, but researchers observed a temporary return of the pupils’ response to light, according to findings reported this month. Importantly, the injections caused no apparent inflammation or serious side effects, providing an early indication that the procedure may be technically feasible.

The research remains highly preliminary. The findings were published as a preprint on August 10 and have not yet undergone peer review, meaning they should not be interpreted as evidence that mitochondrial transplantation is an established treatment for blindness.

Nevertheless, the experiment represents an unusual and potentially important step in a rapidly developing field of medicine built around one of biology’s most fundamental components.

Mitochondria are often described as the power stations of cells. They convert nutrients into adenosine triphosphate, or ATP, the chemical energy used for processes ranging from muscle contraction to nerve signalling.

When mitochondria become dysfunctional, cells with especially high energy requirements — including neurons, heart muscle and retinal cells — can be particularly vulnerable.

Researchers have therefore begun exploring whether healthy mitochondria can be transplanted directly into damaged tissue, where surrounding cells may absorb them and potentially regain some metabolic function.

Previous experimental human procedures have involved mitochondrial transplantation in the heart and brain. The latest work extends that concept to the eye for the first time.

The patient involved in the experiment had suffered a brain haemorrhage that severely damaged both her optic nerve and retina, leaving her almost completely blind. Before treatment, her pupils no longer responded normally when exposed to flashes of light.

Researchers removed mitochondria from cells taken from her own leg muscles and introduced the isolated organelles into the fluid-filled interior of each eye.

Afterwards, the patient’s pupils began responding to light again.

The improvement, however, was temporary. The response declined after approximately four weeks, and the woman did not regain functional vision.

That limitation is scientifically significant.

A returning pupillary response suggests that some elements of the damaged visual pathway retained enough function to react following treatment. But it does not establish that mitochondrial transplantation repaired the retina, regenerated the optic nerve or restored the sophisticated neurological processing required for sight.

Researchers will therefore need to determine exactly what produced the temporary improvement.

It is possible that transplanted mitochondria were absorbed by damaged retinal cells and briefly increased their energy production. Another possibility is that the procedure altered cellular signalling or survival mechanisms without fundamentally repairing the underlying neurological injury.

Temurkhan Ayupov, a mitochondrial biologist at the Institute of Molecular and Clinical Ophthalmology Basel who was not involved in the procedure, told Nature that the experiment provides an early indication that injecting a patient’s own mitochondria into the eye can be performed with relative safety.

Safety is particularly important because the eye presents an unusual environment for experimental medicine.

Its delicate structures contain highly specialized cells, and inflammation inside the eye can itself cause permanent damage. Using mitochondria taken from the patient’s own body could theoretically reduce some immune risks associated with transplanting foreign biological material.

The broader concept behind mitochondrial transplantation is based on evidence that mitochondria can sometimes move between cells naturally.

Scientists have increasingly discovered that these organelles are not always permanently confined to the cells in which they originated. Under certain circumstances, cells can transfer mitochondria to neighbouring cells, potentially helping injured tissue survive.

Researchers are attempting to turn that natural biological phenomenon into a therapeutic technique.

If successful, the implications could extend considerably beyond ophthalmology.

Mitochondrial dysfunction has been implicated in inherited metabolic disorders, neurological diseases, cardiac injury, ageing and several degenerative conditions. Researchers are therefore investigating whether transferring functional mitochondria might support damaged cells in tissues that are otherwise difficult to regenerate.

But major questions remain.

Scientists do not yet fully understand how long transplanted mitochondria survive inside recipient tissues, how efficiently damaged cells absorb them, or whether repeated injections would be necessary.

Another challenge is scale.

An individual cell can contain hundreds or even thousands of mitochondria. Delivering enough functional organelles to significantly influence a large area of damaged tissue could therefore require highly optimized extraction, purification and delivery techniques.

There is also the question of timing.

The patient in the latest experiment had severe structural damage to both her retina and optic nerve. Even if healthy mitochondria temporarily improved cellular metabolism, restoring vision after major nerve injury may require regeneration of neural connections that mitochondrial transplantation alone cannot provide.

Future studies may therefore focus on patients with less advanced retinal damage, where cells remain alive but suffer from impaired energy production.

Such patients could theoretically represent more suitable candidates for metabolic rescue.

The field also illustrates a broader shift taking place in biotechnology.

For decades, medicine has primarily treated cells using drugs, proteins, gene therapy or replacement tissue. Emerging approaches increasingly attempt to manipulate the components inside cells themselves — including RNA, chromosomes, organelles and molecular signalling systems.

Mitochondrial transplantation pushes that concept one step further by treating an entire cellular organelle as a potential therapeutic product.

The experiment arrives amid a particularly active period for regenerative medicine. Nature’s latest science coverage has highlighted parallel advances involving personalized cancer vaccines, long-lived brain organoids, genomic newborn screening and advanced stem-cell therapies.

But the mitochondrial eye transplant stands out because of the simplicity of its central idea: instead of repairing a cell’s damaged energy machinery molecule by molecule, replace part of the machinery itself.

For now, the procedure remains an experimental proof of concept rather than a treatment.

One patient, a temporary biological response and an unreviewed preprint are far from sufficient to establish effectiveness.

Yet the absence of major complications and the brief restoration of a measurable response to light provide researchers with something equally important at this stage — evidence that the idea can be tested in humans.

Whether mitochondrial transplantation ultimately becomes a viable treatment for retinal disease remains uncertain. But the experiment suggests that future regenerative medicine may not be limited to replacing damaged cells.

It may also involve rebuilding them from the inside.